Due to the heterogeneity of mechanisms involved in PI3K/AKT/mTOR activation in ccRCC, a more targeted approach is needed to predict patients benefiting from rapalogs. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.